February 19, 2010
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the American Journal of Transplantation that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.
January 25, 2010
Some of the leading scientists in bioengineering, nanotechnology and pharmaco-genomics will gather on Tuesday, January 26, 2010 to discuss how to harness the tools of these emerging fields to develop new diagnostics and treatments for complex diseases.